Part 4/8:
In a world teetering between corporate success and impending collapse, Beverly grapples with the moral implications of their research. “We might just have the most valuable stock on the planet or more nightmares than we could ever dream of,” she states ominously, pressing the CEO for clarity. The decision before them isn’t merely a business strategy; it could redefine the landscape of biotech.
The narrative heightens as an ominous car crash claims the life of a colleague, intensifying fears about possible sabotage. Beverly finds herself cornered, torn between revealing their research to the world and protecting their groundbreaking work from those who might exploit it.